| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $26.3M | 0.04% | 1.55M | −7.0% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a AUPH trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 9, 2026 | Robertson Stephen POfficer | Sale at price 15.95 per share. | 11.9K | $190.43K |
| Aug 20, 2026 | Robertson Stephen POfficer | Sale at price 16.97 per share. | 21K | $355.95K |
| Jun 1, 2026 | Tang Kevin CChief Executive Officer | Purchase at price 15.28 - 15.35 per share. | 814.6K | $12.46M |
| May 17, 2026 | Hearne Michael S.Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 116.1K | — |
| May 17, 2026 | Robertson Stephen POfficer | Stock Award(Grant) at price 0.00 per share. | 115.5K | — |
| May 17, 2026 | Cole RyanChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 116.1K | — |
| Mar 2, 2026 | Tang Kevin CDirector | Purchase at price 13.90 - 14.38 per share. | 900K | $12.69M |
| Feb 26, 2026 | Miller Joseph MChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 57.2K | — |
| Feb 26, 2026 | Greenleaf Peter SChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 196.4K | — |
| Feb 26, 2026 | Donley Matthew MaxwellChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 58.2K | — |
| Feb 26, 2026 | Robertson Stephen PGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 59.1K | — |
| Feb 26, 2026 | Keenan Gregory M.D.Officer | Stock Award(Grant) at price 0.00 per share. | 40.6K | — |
| Jan 1, 2026 | Miller Joseph MChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 49K | — |
| Jan 1, 2026 | Greenleaf Peter SChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 165.4K | — |
| Jan 1, 2026 | Donley Matthew MaxwellChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 54.2K | — |
| Jan 1, 2026 | Robertson Stephen PGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 48.6K | — |
| Aug 4, 2025 | Tang Kevin CDirector | Purchase at price 10.12 - 11.68 per share. | 1.30M | $13.59M |
| Jul 31, 2025 | Keenan Gregory M.D.Officer | Sale at price 10.50 per share. | 20K | $210.00K |
| Mar 6, 2025 | Keenan Gregory M.D.Officer | Sale at price 8.23 per share. | 8.3K | $68.35K |
| Mar 3, 2025 | Tang Kevin CDirector | Purchase at price 7.85 - 8.09 per share. | 1.60M | $12.71M |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.9 | -2.5 | 4.6 | 3.8 | -0.4 | 10.7 | -12.3 | 8.3 | 0.5 | 2.0 | +3.6% | ||
| 2025 | -11.5 | 0.0 | 1.1 | 2.5 | -4.9 | 8.0 | 9.1 | 29.7 | -7.8 | 19.2 | 22.4 | -1.1 | +77.6% |
| 2024 | -16.1 | -24.1 | -12.4 | 1.6 | 6.5 | 5.4 | 3.0 | 15.8 | 7.6 | -1.6 | 22.9 | 1.4 | −0.1% |
| 2023 | 109.5 | 0.4 | 20.6 | 2.6 | -20.4 | 8.0 | 19.6 | -21.7 | -14.3 | -5.5 | 17.7 | 4.1 | +108.1% |
| 2022 | -27.2 | -26.2 | 0.7 | -16.9 | 9.6 | -10.9 | -18.6 | -10.0 | 2.2 | 8.1 | -36.9 | -15.8 | −81.1% |
| 2021 | 20.8 | -16.2 | -7.3 | 2.2 | 9.4 | -10.7 | 4.6 | 20.1 | 35.9 | 49.5 | -43.0 | 21.4 | +65.4% |
| 2020 | -9.7 | -4.4 | -17.1 | 18.8 | -7.9 | 2.4 | -13.0 | 5.0 | -0.7 | 6.4 | -3.1 | -9.0 | −31.7% |
| 2019 | -7.6 | 7.1 | -3.7 | -5.1 | 5.0 | 1.5 | -3.3 | -9.7 | -7.0 | -9.0 | 63.4 | 155.2 | +197.1% |
| 2018 | 17.0 | -1.7 | -0.4 | 1.2 | 11.0 | -3.4 | -3.9 | 3.1 | 19.0 | -18.1 | 11.4 | 12.5 | +50.6% |
| 2017 | 46.7 | 15.6 | 106.2 | -4.5 | -11.0 | -1.8 | 2.9 | 2.9 | -3.4 | -6.2 | -10.2 | -14.2 | +115.7% |
| 2016 | -19.0 | 18.5 | 22.8 | 0.3 | 1.7 | -6.7 | 22.8 | -43.0 | 55.2 | 0.7 | 0.3 | -30.9 | −15.0% |
| 2015 | -8.0 | 40.3 | -7.2 | -12.4 | -8.1 | -14.0 | 22.5 | -8.1 | -16.5 | 2.8 | -13.7 | -2.0 | −32.1% |
| 2014 | 12.5 | 12.5 | -10.1 | +13.8% |
Buy / hold / sell counts
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.